Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Equity Average (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Equity Average readings, the most recent being $62.7 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 493.56% to $62.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.7 million, a 493.56% increase, with the full-year FY2025 number at $12.3 million, down 61.06% from a year prior.
  • Equity Average hit $62.7 million in Q4 2025 for Aligos Therapeutics, down from $86.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $207.6 million in Q1 2021 to a low of $10.6 million in Q4 2024.
  • Median Equity Average over the past 5 years was $90.6 million (2023), compared with a mean of $107.9 million.
  • Biggest five-year swings in Equity Average: plummeted 85.62% in 2024 and later soared 493.56% in 2025.
  • Aligos Therapeutics' Equity Average stood at $200.9 million in 2021, then tumbled by 43.77% to $113.0 million in 2022, then crashed by 34.97% to $73.5 million in 2023, then plummeted by 85.62% to $10.6 million in 2024, then soared by 493.56% to $62.7 million in 2025.
  • The last three reported values for Equity Average were $62.7 million (Q4 2025), $86.8 million (Q3 2025), and $109.2 million (Q2 2025) per Business Quant data.